



CIN: L24100MH1988PLC343805

Reg. Office : Office No.9, K Raheja Prime Sagbaug Road,
Marol, Andheri (East), Mumbai - 400059

info@remediumlifecare.com

+91 8433895251



REMEDIUM LIFECARE LTD.
(Formerly known as "Roxy Exports Limited")

February 14, 2025

To,
Listing Compliance Department
BSE Ltd.
P. J. Towers, Dalal Street,
Mumbai - 400 001

Scrip Code: 539561 / REMLIFE

Sub: Outcome of the Board Meeting held on February 14, 2025.

Dear Sir/Madam,

This is to inform you that the Board of Directors of the Company at their meeting held today, i.e. on Friday, February 14, 2025 has inter alia transacted the following business:

1. Considered and approved the unaudited standalone financial results for the Quarter and Nine Months ended December 31, 2024 along with Limited Review Report of the Statutory Auditors.

Pursuant to Clause 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Standalone Financial Results of the Company for the Quarter and Nine Months ended December 31, 2024 together with the Limited Review Report of the Statutory Auditors thereon.

The meeting of the Board of Directors of the company commenced at 5:00 pm and concluded at 6:30 pm.

We request you to kindly take the above on record.
Thanking you

Yours faithfully,

For Remedium Lifecare Limited



Neeraj Yadav
Company Secretary & Compliance Officer

Encl: As above.

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar, M.G. Road No.6, Goregaon West.
Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior - 474002 (M.P.)

Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Financial Results of Remedium Lifecare Limited (formerly known as Roxy Exports Limited) pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).

To,

**The Board of Directors of Remedium Lifecare Limited
(formerly known as Roxy Exports Limited)**

1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of **Remedium Lifecare Limited (formerly known as Roxy Exports Limited)** ('the Company') for the quarter ended December 31, 2024 and year to date results for the period April 01, 2024 to December 31, 2024, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No.201, Nav Sudhir CHS Ltd, 113, Tilak Nagar, M.G. Road No.6, Goregaon West,
Mumbai- 400 104. Mob- 7021416997, 07738364419 Email-cpatul14@gmail.com

Head Office: "Deepa - Lakshmi" 106, Kherapati Colony, Gwalior - 474002 (M.P.)

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For TAORI SANDEEP & ASSOCIATES

Chartered Accountants

FRN: 007414C



Atul Jain
Partner
M. No. 048920



Place: Mumbai

Date: 14th February, 2025

UDIN: 25048920BMNQNC2810

REMIIDIUM LIFECARE LIMITED

REGD. OFFICE: Office No.9, K Raheja Prime, Marol Industrial Estate Behind Ravi Vihar Hotel, Sagbaug Road, Marol Naka, Andheri East, Mumbai 400059
E-mail: info@remidiumlifecare.com;
CIN: L24100MH1988PLC343805

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31st December 2024

(₹ in Lakhs Except per share data)

Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
	31st December, 2024	30th September, 2024	31st December, 2023	31st December, 2024	31st December, 2023	31st March, 2024
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I. Revenue from Operations	3,815.08	2,508.15	1,83,417.83	14,092.85	2,63,321.30	4,04,170.67
II. Other Income	743.07	82.22	1,411.60	1,014.32	1,818.84	2,108.11
III. Total Income (I +II)	4,558.14	2,590.38	1,84,829.43	15,107.17	265,140.14	4,06,278.78
IV. Expenses						
Cost of Material Consumed	-	-	-	-	-	-
Purchases of Stock-in-trade	7,770.12	11,539.30	1,89,160.96	34,327.36	2,70,497.96	4,12,728.50
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	-3,726.74	-9,643.85	-11,321.59	-20,780.74	-14,522.26	-12,590.97
Employee Benefits Expenses	20.29	23.79	17.05	66.33	65.96	84.27
Finance Costs	88.36	281.17	2.59	369.53	2.59	387.30
Depreciation and amortisation expenses	0.97	0.97	1.34	2.90	4.26	5.67
Other Expenses	299.24	143.10	91.39	543.31	446.61	618.59
Total Expenses (IV)	4,452.23	2,344.47	1,77,951.73	14,528.70	2,56,495.11	4,01,233.35
V. Profit/(Loss) before exceptional items and tax (III- IV)	105.91	245.91	6,877.70	578.47	8,645.02	5,045.42
VI. Exceptional items	-	-	-	-	-	-
VII. Profit/(Loss) before tax (V-VI)	105.91	245.91	6,877.70	578.47	8,645.02	5,045.42
VIII. Tax Expense						
(1) Current tax	29.47	68.41	2,296.05	160.93	2,886.06	1,774.34
(2) Deferred tax	-	-	-	-	-	-1.93
(3) Previous Year Tax	-	-	-	-	-	-
Total Tax	29.47	68.41	2,296.05	160.93	2,886.06	1,772.41
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	76.45	177.50	4,581.65	417.54	5,758.97	3,273.02
X. Profit/(Loss) from discontinued operations	-	-	-	-	-	-
XI. Tax expense of discontinued operations	-	-	-	-	-	-
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-	-
XIII. Profit/(Loss) for the period (IX+XII)	76.45	177.50	4,581.65	417.54	5,758.97	3,273.02
XIV. Other Comprehensive Income	-	-	-	-	-	-
(A) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
(B) (i) Items that will be classified to profit or loss	-	-	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
XV. Total Comprehensive Income for the period (XIII+XIV) (Comprising Profit (Loss) and Other Comprehensive Income for the Period)	76.45	177.50	4,581.65	417.54	5,758.97	3,273.02
XVI. Earnings per equity share (for continuing operation):						
(1) Basic	0.02	0.04	22.73	0.10	28.57	3.25
(2) Diluted	0.02	0.04	22.73	0.10	28.57	3.25

Notes:

- The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on 14th February, 2025. The Statutory Auditors have carried out a "Limited Review" of the Financial results for the Quarter and Nine Months ended 31st December, 2024.
- The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification
- The Company has incorporated a wholly own subsidiary but since its operations did not started till 31.12.2024 the company has not prepared consolidated financial statement.
- As the Company's business activity falls within a single segment, therefore "Segment Reporting" is not applicable.

For Remidium Lifecare Limited


ADARSH MUNJAL
(WHOLE TIME DIRECTOR)
DIN : 07304004



Place : Mumbai
Date : 14.02.2025